DMBT1 (deleted in malignant brain tumors) is a candidate tumor suppressor gene that has been mapped to chromosome 10q25.3-q26.1, a region in which frequent loss of heterozygosity (LOH) has been observed in several human tumors. Since DMBT1 is highly expressed in the lung, we analyzed LOH at the DMBT1 locus and expression of this gene in lung cancer. Thirty-five (53%) of 66 primary lung cancers showed LOH, and diminished expression of DMBT1 was observed in 20 (91%) of 22 lung cancer cell lines: three (14%) of them showed loss of expression. We further determined the primary structure of DMBT1 and analyzed genetic alterations in this gene using 23 lung cancer cell lines. Two (9%) of them had homozygous deletion within the gene, and two cell lines had genetic aberrations: one was a rearrangement involving exons 5 and 6, and the other was a missense mutation at codon 52. These results suggest that inactivation of the DMBT1 gene plays an important role in human lung carcinogenesis.
Allelic loss is a hallmark of inactivation of tumor suppressor genes. In lung cancer, loss of chromosome arms 1p, 2q, 3p, 5q, 7q, 9p, 10q, 13q, 16q, and 17p has been reported to date. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the responsible gene has not yet been identified in the great majority of these loci. PTEN was isolated from chromosome 10q23.3, [12] [13] [14] and frequent somatic mutation of this gene was observed in endometrial carcinomas [15] [16] [17] and endometrial hyperplasias, [18] [19] [20] the putative premalignant lesions of endometrial cancer. However, this gene was not frequently mutated in lung cancer in Japanese patients. 21) Recently, the DMBT1 (deleted in malignant brain tumors) gene has been cloned from 10q25.3-q26.1. 22) DMBT1 encodes a protein that contains eight tandem repeats of the SRCR (scavenger receptor cysteine-rich) domains that are highly homologous, with 94-99% identity. 22) The SRCR protein group contains diverse members, some of which have been linked to the triggering of proliferation and/or differentiation processes [23] [24] [25] [26] ; one member, hensin, plays a role in switching the polarity of epithelial cells by mediating contacts between the extracellular matrix and cell-surface proteins.
27) The ZP domain is included in transforming growth factor β receptor type III (TGFβRIII), which regulates the association of TGF-β with the signaling receptors. 28, 29) Hence, there is a possibility that this gene works as a tumor suppressor.
Since the expression of the DMBT1 gene was high in the lung, we hypothesized that genetic alteration of this gene is involved in human lung carcinogenesis. First we analyzed loss of heterozygosity (LOH) at the DMBT1 locus in 66 primary lung cancer tissues (34 squamous cell carcinomas, 20 adenocarcinomas, 7 large cell carcinomas, and 5 small cell carcinomas) using a microsatellite marker D10S587. Tumors and corresponding normal tissues were frozen in liquid nitrogen immediately after resection and stored at −80°C until use. In each case, a part of the tumor specimen was fixed in formalin and examined histopathologically, and only specimens of lung cancers in which contamination by normal cells was less than 50% of the total were used for this analysis. Typical examples are shown in Fig. 1 , and the results are summarized in Table I . Thirty-five (53%) of 66 lung cancers showed LOHs, and there was no association between incidence of LOH and histologic diagnosis.
We then characterized the genomic structure of DMBT1. Six overlapping BAC (bacterial artificial chromosome) clones covered the entire DMBT1 gene (see Fig. 2 ). These BAC clones were purchased from Research Genetics (Huntsville, AL). The exon-intron boundaries were determined and it was found that this gene consists of 40 exons (see Fig. 2 ). The repeating regions encoding SRCR and SID (SRCR interspersed domain) were highly homologous not only in the exonic, but also in the intronic sequences. Each repeat unit consisting of one SRCR and one SID was encoded by three exons. Two candidate regions for exons that may encode additional SRCR domains were also found in intron 12 (see open boxes in Fig. 2) . Both of the candidate exons are 324 bp in length with a continuous reading frame and flanked by AG and GT, being very similar to other SRCR-coding exons. These regions may be involved in alternative splicing mechanisms and may explain the previous finding of several different-sized DMBT1 transcripts. 22) 5′-RACE using the lung mRNA was also performed and afforded a 464-base sequence upstream from the 5′ end of the published cDNA sequence: this sequence was identical with the genomic sequence. Nucleotide sequences of the exons, surrounding intronic regions, and 5′-flanking region of the gene have been deposited in the DDBJ, GenBank, and EMBL databases under the accession numbers AB020812 through AB020851.
We next analyzed the expression of DMBT1 by reversetranscription polymerase chain reaction (RT-PCR) in 22 human lung cancer cell lines. 30) A primer pair DM11 (5′-TCCAGGTCGAGGAAGTCCA-3′) in exon 39 and DM8 IDM75  TAGCAGGTGACATGTGCCTG  DM6  GCCTGAGTGTTGACTGAGG  317  60  (+)  39-3′  DM11  TCCAGGTCGAGGAAGTCCA  IDM50 TACTGGGAACTGCAGTTCATC  347  60  (+)  40-5′  IDM7  GTACAACTGAGTCATGAAGG  DM8  CTGCACACCACCATTTTACA  199  58  (+)  40-3′  DM13  TCGCCGTCTCTTCGCATTG  DM10  CCCAAGTCCCCGAGTCAG  303  60  (+) a) DMSO, dimethyl sulfoxide. b) IDM27 is a mixture of 5′-TACCCTGAGTGTGGAAC-3′ and 5′-TACCTTGAGTGTGGAAC-3′.
(5′-CTGCACACCACCATTTACA-3′) in exon 40 was used. Twenty (91%) of 22 cell lines showed diminished expression: among these, three (SBC-3, LK-2 and Sato T) showed loss of expression (see Fig. 3A ). Expression of hMSH2 was monitored as the control. Homozygous deletions were also surveyed by PCR amplification of exons 1, 29, 35, 39, and intron 12 using the 22 cell lines as well as one additional lung cancer cell line (VMRC-LCP). As shown in Fig. 3B , two cell lines, LK-2 and RERF-LC-MS, did not produce any PCR products when we used two primer pairs g14 (primers g14f2 and g14r3) and g14ext (primers g14extf2 and g14extr1), both in intron 12. 22) These results strongly suggested homozygous deletion, but the possibility of insertion/deletion polymorphism could not be totally excluded. We could not identify the precise region of the homozygous deletion due to the very high homology of the genomic sequence surrounding intron 12. LK-2, one of the cell lines with homozygous deletion, also showed loss of expression of DMBT1.
We further examined genetic alterations of the DMBT1 gene in 23 lung cancer cell lines. Primers used for mutation analyses are shown in Table II . Due to the high homology in exonic as well as intronic sequences in the repeated region, it was not possible to amplify some exons individually. The entire coding exons as well as surrounding regions of the gene were surveyed, and two mutations were found as shown in Fig. 4 . In A549, a heterozygous missense mutation from TCG to TGG at codon 52 that causes an amino acid change from Ser to Trp was observed (see Fig. 4A ). This mutation was also reported in a lung cancer cell line Calu-1 by Wu et al. 31) HS-24 harbored a rearrangement involving exons 5 and 6 in one of the alleles as schematically shown in Fig. 4B . Although 198 bp 177 bp C exons 5 and 6 are highly homologous, some amino acid alterations may influence the function of the DMBT1 protein. This rearrangement, confirmed by PCR amplification as shown in Fig. 4C , was not observed in DNA samples of 50 normal volunteers.
In summary, the great majority of lung cancer cell lines showed diminished expression or loss of expression of DMBT1, and two (9%) of 23 cell lines had a homozygous deletion. Genetic alteration was also observed in two cell lines. While we were preparing the manuscript, Wu et al.
reported frequent loss of expression of DMBT1 in lung cancer. 31) Our results along with those of Wu et al. suggested that inactivation of the DMBT1 gene plays an important role in lung carcinogenesis.
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